However, the analyses here along with the growing number of studies observing myostatin as a biomarker in the context of chronic and metabolic diseases reveals the complex and somewhat unpredictable behavior of the myokine (Arrieta et al., 2019; Brandt et al., 2012; Elliott et al., 2012; Hittel et al., 2009). Here, MSTN is linked to metabolic disease.